RBC Capital maintains Arxis at Outperform, raises price target to $64 from $60

What happened

RBC Capital kept an Outperform rating on Eli Lilly and raised its price target to $1600 from $1500 per share. RBC also kept an Outperform rating on Arxis and raised its price target to $64 from $60, a 6.7% increase. No verified reactions were recorded.

Global impact / market context

An Outperform rating means the analyst expects the stock to do better than the market. A higher price target suggests the analyst sees more room for the stock to rise. For ordinary investors, these are opinions from one firm, not guarantees. The Arxis target implies 16.5% upside from the October 29 close of $54.93.

What to watch

1. Check whether other research firms also raise their targets for Eli Lilly, because more firms agreeing would suggest a broader view rather than one opinion.
2. Check whether other research firms also raise their targets for Arxis, because one firm alone may not reflect the wider market view.
3. Check whether the Arxis share price moves toward the $64 target or away from it, because the target implies 16.5% upside from the October 29 close of $54.93.

Affected assets

• Arxis

Evidence

• Infoway News — Eli Lilly Is Maintained at Outperform by RBC Capital 2026-10-30T15:58:00+00:00
• Infoway News — Arxis Price Target Raised to $64.00/Share From $60.00 by RBC Capital 2026-10-30T15:22:00+00:00
• Infoway News — RBC Capital maintains Arxis at Outperform, raises price target to $64 from $60 2026-10-30T15:11:45+00:00
• Incident timeline — Eli Lilly Is Maintained at Outperform by RBC Capital
• Incident timeline — Arxis Price Target Raised to $64.00/Share From $60.00 by RBC Capital
• Incident timeline — RBC Capital maintains Arxis at Outperform, raises price target to $64 from $60